Butylphthalide plus tenecteplase for mild disabling stroke
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether adding butylphthalide (a drug that improves blood flow) to the standard clot-busting medicine tenecteplase can help people with mild but disabling strokes recover better. If you have had a mild stroke within the last 4.5 hours and are 18–80, this study might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your stroke symptoms (like arm weakness or trouble talking) started less than 4.5 hours ago.
- Your stroke is mild but still limits your ability to move one side or speak – rated between 2 and 5 on a stroke scale.
- You were able to do daily activities on your own before this stroke (no major disability).
- You are willing and able to sign a consent form for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if butylphthalide, a drug that may improve blood flow, helps people with a narrowed artery in the brain (the middle cerebral artery) after a recent stroke or mini-stroke. It is for people aged 55-75 with at least one risk factor like high blood pressure or diabetes.
This trial tests whether a medication called butylphthalide can help reduce brain swelling that sometimes occurs after emergency endovascular treatment (a minimally invasive procedure to restore blood flow) for certain types of stroke.
This trial tests if butylphthalide, a medicine given by mouth, can help prevent long-term thinking and memory problems after a minor stroke. It is for people who had a very mild stroke and enrolled soon after.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests a clot-busting drug called tenecteplase for patients having a mild stroke (with weakness on one side or trouble speaking) who can get treatment within 4.5 hours. The goal is to see if this drug helps improve blood flow and reduces disability.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Hear when a new Mild Disabling Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.